Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nomifensine: diagnostic test in hyperprolactinemic states.

E E Müller, A R Genazzani, S Murru

    The Journal of Clinical Endocrinology and Metabolism
    |December 1, 1978
    PubMed
    Summary

    Nomifensine, an antidepressant, can inhibit prolactin (PRL) levels in non-tumor patients. This neuropharmacological test may help detect pituitary adenomas by observing PRL level suppression.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.

    Anticancer research·2001
    Same author

    Serum allopregnanolone in women with postpartum "blues".

    Obstetrics and gynecology·2001
    Same author

    The use of a starting dose of recombinant follicle stimulating hormone for controlled ovarian hyperstimulation: a randomized pilot study.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
    Same author

    Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
    Same author

    Ovarian follicular fluid contains immunoreactive estriol: lack of correlation with estradiol concentrations.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000
    Same author

    Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2000

    Area of Science:

    • Neuropharmacology
    • Endocrinology

    Background:

    • Nomifensine is an antidepressant that enhances dopamine neurotransmission by inhibiting dopamine reuptake.
    • Hyperprolactinemia is a condition characterized by elevated prolactin levels.

    Purpose of the Study:

    • To investigate the effect of nomifensine on plasma prolactin (PRL) levels in women.
    • To evaluate nomifensine's potential as a diagnostic tool for pituitary adenomas.

    Main Methods:

    • Oral administration of nomifensine (100 or 200 mg) to postpartum lactating women and women with nonpuerperal hyperprolactinemia.
    • Measurement of plasma PRL levels over 5 hours post-administration.
    • Comparison of PRL level changes in patients with and without PRL-secreting tumors.

    Main Results:

    • Nomifensine significantly inhibited plasma PRL levels in postpartum and non-tumor hyperprolactinemia groups.
    • In patients with PRL-secreting tumors, nomifensine failed to lower plasma PRL levels.
    • Non-suppressibility of PRL levels to nomifensine indicated pituitary microadenoma in two patients.

    Conclusions:

    • Acute nomifensine administration can suppress prolactin levels in individuals without pituitary adenomas.
    • The lack of PRL suppression by nomifensine may serve as a diagnostic indicator for pituitary adenomas.
    • Nomifensine testing shows promise as a neuropharmacological tool for differentiating pituitary adenoma presence.

    Related Experiment Videos